Cargando…

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Ritonavir is the most potent cytochrome P450 (CYP) 3A4 inhibitor in clinical use and is often applied as a booster for drugs with low oral bioavailability due to CYP3A4-mediated biotransformation, as in the treatment of HIV (e.g., lopinavir/ritonavir) and more recently COVID-19 (Paxlovid or nirmatre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loos, Nancy H. C., Beijnen, Jos H., Schinkel, Alfred H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456214/ https://www.ncbi.nlm.nih.gov/pubmed/36077262 http://dx.doi.org/10.3390/ijms23179866

Ejemplares similares

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
por: Loos, Nancy H.C., et al.
Publicado: (2023)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
por: Li, Wenlong, et al.
Publicado: (2021)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Wang, Yaogeng, et al.
Publicado: (2021)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
por: F. Martins, Margarida L., et al.
Publicado: (2022)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry
por: Susam, M. Merve, et al.
Publicado: (2022)

Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates
por: Kandel, Sylvie E., et al.
Publicado: (2021)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

SAT340 Matters Of The HAART - Ritonavir Induced CYP3A4 Inhibition of Intranasal Fluticasone Leading To Cushing’s Syndrome
por: Ramachandran, Aishwarya, et al.
Publicado: (2023)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

Mechanisms of PIEZO Channel Inactivation
por: Zhou, Zijing, et al.
Publicado: (2023)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
por: Adeloye, Temitope, et al.
Publicado: (2018)

Explaining the Release Mechanism of Ritonavir/PVPVA Amorphous Solid Dispersions
por: Krummnow, Adrian, et al.
Publicado: (2022)

Mechanisms of Choice in X-Chromosome Inactivation
por: Furlan, Giulia, et al.
Publicado: (2022)

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
por: Deodhar, Malavika, et al.
Publicado: (2020)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment
por: Samuels, Eric R., et al.
Publicado: (2022)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
por: Uzunova, Katya, et al.
Publicado: (2020)

Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2022)

Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours
por: Vermunt, Marit A. C., et al.
Publicado: (2021)

Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength
por: Samuels, Eric R., et al.
Publicado: (2021)

Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition
por: Deodhar, Malavika, et al.
Publicado: (2021)

Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action
por: Derissen, Ellen J. B., et al.
Publicado: (2020)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

Spotlight on CYP4B1
por: Röder, Annika, et al.
Publicado: (2023)

Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase
por: Stuehr, Dennis J., et al.
Publicado: (2021)

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
por: Ceresa, Brian P., et al.
Publicado: (2008)

Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins
por: Zeng, Meiqi, et al.
Publicado: (2015)

No relation between docetaxel administration route and high‐grade diarrhea incidence
por: Hendrikx, Jeroen J. M. A., et al.
Publicado: (2020)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6agoiu4jdjrshiul0rkcuddhla